Episode 3: The execution challenge

The body could become the bioreactor. But how do we build the infrastructure around it?

Making in vivo therapies a reality requires a new approach to manufacturing, scale, and access.

In Episode 3 of the body as a bioreactor series, we explore the execution challenge: how manufacturing, infrastructure, and regulatory approaches may need to evolve as genomic medicines move from centralized facilities towards more distributed models.

In this episode, you will learn:

• From centralized to distributed manufacturing: How the shift towards in vivo therapeutics could reduce complex ex vivo operations and bring manufacturing closer to patients.
• Scaling in both directions: Why the future may require manufacturing approaches that can support everything from global population-scale therapies to medicines designed for a single patient.
• Manufacturing closer to the patient: How more distributed production could improve accessibility, reduce logistical complexity, and help tailor medicines to local needs.
• Building consistency at every scale: Why robust, standardized, and reproducible manufacturing processes will be essential for maintaining safety and quality across different manufacturing environments.
• A new framework for trust: How regulatory, quality, and testing approaches may need to evolve as genomic medicines become more distributed and increasingly personalized.

By the end, you will understand why the future of in vivo genomic medicine isn’t only about developing new therapies. It also depends on building the manufacturing infrastructure, standards, and processes needed to make those therapies available to more patients.